Ann Mongan, director of translational research at BMS, outlines how biomarkers hold pivotal roles in clinical trials.

Historically, pregnant women have been excluded from clinical trials due to safety concerns, but the WHO is pushing for change.

CatalYm has commenced dosing the first subject in its Phase II/III VINCIT trial, assessing the safety and efficacy of its lead anti-GDF-15 antibody, visugromab, in cancer-associated cachexia.

Epitopea has secured approval from the MHRA and the REC in the UK for its OVACT CTA targeting advanced high-grade serous ovarian cancer.

The MDX-2003-101 study will investigate MDX2003’s tolerability, pharmacokinetics, safety, and immune activity. Credit: Sai Thaw Kyar/Shutterstock.com. OPKO Health subsidiary ModeX Therapeutics has ...

At AAN 2026, Argenx announced positive results from the Phase III, double-blind, placebo-controlled, ADAPT SERON study of Vyvgart.

At AAN 2026, Cabaletta Bio announced positive results from the Phase I/II open-label, RESET-MG study of rese-cel in patients with gMG.

Currently in Phase I development, TherVacB is a therapeutic vaccine candidate designed as an immune therapy for chronic hepatitis B patients.

Approval for Xeltis’s aXess device was based on pivotal trial data that demonstrated 79% secondary patency and a patency-related reintervention rate of 1.3 per patient year.

Roche has reported new findings from the Phase III METEOROID trial of Enspryng in adults and adolescents with MOGAD.

The IgAN study was run by AstraZeneca’s rare disease arm,, Alexion. Credit: Mats Wiklund / Shutterstock.com AstraZeneca plans to seek accelerated approval of Ultomirisin kidney disease after the drug ...